Crinetics Pharmaceuticals (CRNX) Income towards Parent Company (2017 - 2025)
Historic Income towards Parent Company for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$130.1 million.
- Crinetics Pharmaceuticals' Income towards Parent Company fell 6932.76% to -$130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.7 million, marking a year-over-year decrease of 5482.52%. This contributed to the annual value of -$297.4 million for FY2024, which is 4218.87% down from last year.
- According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Income towards Parent Company is -$130.1 million, which was down 6932.76% from -$115.7 million recorded in Q2 2025.
- Crinetics Pharmaceuticals' 5-year Income towards Parent Company high stood at -$22.9 million for Q1 2021, and its period low was -$130.1 million during Q3 2025.
- In the last 5 years, Crinetics Pharmaceuticals' Income towards Parent Company had a median value of -$53.4 million in 2023 and averaged -$60.8 million.
- Per our database at Business Quant, Crinetics Pharmaceuticals' Income towards Parent Company tumbled by 2023.15% in 2023 and then crashed by 6932.76% in 2025.
- Crinetics Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$30.8 million in 2021, then crashed by 48.18% to -$45.7 million in 2022, then fell by 22.53% to -$55.9 million in 2023, then plummeted by 43.69% to -$80.4 million in 2024, then crashed by 61.85% to -$130.1 million in 2025.
- Its Income towards Parent Company stands at -$130.1 million for Q3 2025, versus -$115.7 million for Q2 2025 and -$96.6 million for Q1 2025.